Pertussis re-emergence in the post-vaccination era

BMC Infectious Diseases

Maurizio de Martino¹  Luisa Galli¹  Alessia Stival¹  Elena Chiappini¹ 

[1] Anna Meyer University Hospital, Department of Health Sciences, University of Florence, Florence, Italy

关键词: Vaccine;    Pertussis;    Children;   

Others  :  1149104
DOI  :  10.1186/1471-2334-13-151

 received in 2012-12-20, accepted in 2013-03-19,  发布年份 2013

【 摘 要 】

Background

Resurgence of pertussis in the post-vaccination era has been reported in Western countries. A shift of cases from school-age children to adolescents, adults and children under 1 year of age has been described in the last decade, and mortality rates in infants are still sustained. We aimed to review and discuss the possible vaccination strategies which can be adopted in order to improve the pertussis control, by searches of Pubmed, and websites of US and European Centers for Disease Control and Prevention, between 1st January 2002, and 1st March 2013.

Discussion

The following vaccination strategies have been retrieved and analysed: the cocooning strategy, the immunization of pregnant women and newborns, vaccination programs for preschool children, adolescents, adults and health-care workers. Cost-effectiveness studies provide some contrasting data, mainly supporting both maternal vaccination and cocooning. Adolescent and/or adult vaccination seems to be cost-effective, however data from observational studies suggest that this vaccination strategy, used alone, leads to a reduced pertussis burden globally, but does not affect the disease incidence in infants. Moreover, substantial logistical and economic difficulties have to be overcome to vaccinate the largest number of individuals.

Summary

The simultaneous use of more than one strategy, including cocooning strategy plus vaccination of adolescents and adults, seems to be the most reasonable preventive measure. The development of new highly immunogenic and efficacious pertussis vaccines continues to be a primary objective for the control of pertussis.

【 授权许可】

   
2013 Chiappini et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]World Health Organization: WHO-recommended surveillance standard of pertussis. http://www.who.int/immunization_monitoring/diseases/pertussis_surveillance/en/index.html webcite (accessed Dec 3, 2012)
• [2]Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE: EUVAC-NET group. Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005, 24:761-765.
• [3]Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, Chavez G: California pertussis epidemic, 2010. J Pediatr 2012, 1:1091-1096.
• [4]Cherry JD: Epidemic pertussis in 2012 – The resurgence of a vaccine-preventable disease. N Engl J Med 2012, 367:785-787.
• [5]CDC: Pertussis epidemic – Washington. MMWR 2012, 61:517-522.
• [6]Billingsley M: Pregnant women in UK are offered whooping cough vaccine to protect newborns. BMJ 2012, 345:e6594.
• [7]Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, Tozzi AE, Damme P: Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011, 11:557-570.
• [8]Bechini A, Tiscione E, Boccalini S, Levi M, Bonanni P: Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations. Vaccine 2012, 30:5179-5190.
• [9]Cherry JD, Tan T, Wirsing von Konig CH, Forsyth KD, Thisyakorn U, Greenber D, Johnson D, Marchant C, Plotkin S: Clinical definitions of pertussis: summary of a global pertussis initiative roundtable meeting, February 2011. Clin Infect Dis 2012, 54:1756-1764.
• [10]Cherry JD: Why do pertussis vaccines fail? Pediatrics 2012, 129:968-970.
• [11]Healy CM, Rench MA, Castagnini LA, Baker CJ: Pertussis immunization in a high-risk postpartum population. Vaccine 2009, 27:5599-5602.
• [12]Kmietowicz Z: Pertussis cases rise 10-fold among older children and adults in England and Wales. BMJ 2012, 345:e5008.
• [13]European Centre for Disease Prevention and Control (ECDC): Annual epidemiological report on communicable diseases in Europe. 2007. Available at: http://ecdc.europa.eu/en/publications/Publications/0706_SUR_Annual_Epidemiological_Report_2007.pdf webcite (accessed Dec 3, 2012)
• [14]European Centre for Disease Prevention and Control (ECDC): Annual epidemiological report on communicable diseases in Europe – 2008. Available at: http://ecdc.europa.eu/en/publications/Publications/0812_SUR_Annual_Epidemiological_Report_2008.pdf webcite (accessed Dec 3, 2012)
• [15]European Centre for Disease Prevention and Control (ECDC): Annual epidemiological report on communicable diseases in Europe – 2009. Available at: http://ecdc.europa.eu/en/publications/Publications/0910_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf webcite (accessed Dec 3, 2012)
• [16]European Centre for Disease Prevention and Control (ECDC): Annual epidemiological report on communicable diseases in Europe – 2010. Available at: http://ecdc.europa.eu/en/publications/Publications/1011_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf webcite (accessed Dec 3, 2012)
• [17]European Centre for Disease Prevention and Control (ECDC): Annual epidemiological report on communicable diseases in Europe – 2011. Available at: http://ecdc.europa.eu/en/publications/Publications/1111_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf webcite (accessed Dec 3, 2012)
• [18]Munoz F, Englund J: Infant pertussis: is cocooning the answer? Clin Infect Dis 2011, 53:893-896.
• [19]Zhang L, Prietsch SOM, Axelsson I, Halperin SA: Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 2012, 3:1-146.
• [20]America Academy of Pediatrics Commitee on Infectious Diseases: Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 2006, 117:965-978.
• [21]Locht C, Mielcarek N: New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol Med Microbiol 2012, 66:121-133.
• [22]Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A: Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001, 108:e81.
• [23]Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, Blackwelder WC, Jansen DL, Meade BD: Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 2000, 105:e11.
• [24]McCormack PL: Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization. Drugs 2012, 72:1765-1791.
• [25]Scott LJ: Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults. BioDrugs 2010, 24:387-406.
• [26]Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heiibel H: Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the study of pertussis vaccines. Lancet 1997, 350:1569-1577.
• [27]Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, Greenberg DP, Keitel W, Barenkamp S, Bernstein DI, Edelman R, Edwards k, APERT Study Group: Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005, 353:1555-1563.
• [28]Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, Sanden G, Mboup S, Hoffenbach A, Knudsen K, Guiso N, Wassilak S, Cadoz M: A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997, 15:1606-1612.
• [29]Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, Uberall M, Laussucq S, Eckhardt T, Meyer M, Engelhardt R, Christenson P: A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998, 101:1-11.
• [30]Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J: A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-355.
• [31]Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR: CDC. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998–2001. Pediatrics 2005, 116:285-294.
• [32]Rank C, Quinn HE, McIntyre PB: Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J 2009, 28:152-153.
• [33]Lugauer S, Heininger U, Cherry JD, Stehr K: Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002, 161:142-146.
• [34]Campbell H, Amirthalingam G, Andrews N, Fry NK, George RC, Harrison TG, Miller E: Accelerating control of pertussis in England and Wales. Emerg Infect Dis 2012, 18:38-47.
• [35]Jenkinson D: Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed) 1988, 296:612-614.
• [36]Witt MA, Katz PH, Witt DJ: Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012, 54:1730-1735.
• [37]ECDC: Vaccination schedules. Available at: http://ecdc.europa.eu/en/activities/surveillance/euvac/schedules webcite (accessed Dec 18, 2012)
• [38]Government of Western Australia: Department of Public Health. Pertussis (whooping cough). Available at: http://www.public.health.wa.gov.au/2/274/2/pertussis_whooping_cough_fact_sheets.pm webcite (accessed Dec 18, 2012)
• [39]Centers for Disease Control and Prevention (CDC): Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months. Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011, 60:1424-1426.
• [40]Gall SA, Myers J, Pichichero M: Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011, 334:e1-e5.
• [41]Zheteyeva YA, Moro PL, Tepper NK, Rasmussen SA, Barash FE, Revzina NV, Kissin D, Lewis PW, Yue X, Haber P, Tokars JI, Vellozzi C, Broder KR: Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012, 59:e1-e7.
• [42]Healy CM, Rench MA, Halasa NB, Edwards KM, Baker CJ: Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004, 190:335-340.
• [43]Gall SA: Prevention of pertussis, tetanus, and diphtheria among pregnant, postpartum women, and infants. Clin Obstet Gynecol 2012, 55:498-509.
• [44]Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P: Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011, 30:608-610.
• [45]Healy CM, Rench MA, Baker CJ: Importance of timing of maternal Tdap immunization and protection of young infants. Clin Infect Dis Clin 2013, 56:539-544. accessed Oct 26, 2012
• [46]Esposito S, Bosis S, Morlacchi L, Baggi E, Sabatini C, Principi N: Can infants be protected by means of maternal vaccination? Clin Microbiol Infect 2012, 5:85-92.
• [47]Halperin BA, Halperin SA: The reemergence of pertussis and infant deaths: is it time to immunize pregnant women? Future Microbiol 2011, 6:367-369.
• [48]Englund JA, Anderson EL, Reed GF, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Rennels MB, Deforest A, Meade BD: The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995, 96:580-584.
• [49]Dalhousie University: Pertussis maternal immunization study. Identifier NCT00553228. Available at: http://www.clinicaltrials.gov/show/nct00553228 webcite (accessed Dec 5, 2012)
• [50]National Institute of Allergy and Infectious Diseases (NIAID): Pertussis vaccine in healthy pregnant women. Identifier NCT00707148. http://www.clinicaltrials.gov/show/nct00707148 webcite (accessed Dec 5, 2012)
• [51]Halasa NB, O’Shea A, Shi JR, LaFleur BJ, Edwards KM: Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 2008, 153:327-332.
• [52]Belloni C, De Silvestri A, Tinelli C, Avanzini MA, Marconi M, Strano F, Rondini G, Chirico G: Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003, 111:1042-1045.
• [53]Knuf M, Schmitt HJ, Wolter J, Schuerman L, Jacquet JM, Kieninger D, Siegrist CA, Zepp F: Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008, 152:655-660.
• [54]Knuf M, Schmitt HJ, Jacquet JM, Collard A, Kieninger D, Meyer CU, Siegrist CA, Zepp F: Booster vaccination after neonatal priming with acellular pertussis vaccine. J Pediatr 2010, 156:675-678.
• [55]Wood N, McIntyre P, Marshall J, Roberton D: Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 2010, 29:209-215.
• [56]Sharma SK, Pichichero ME: Functional deficits of pertussis-specific CD4+ T cells in infants compared to adults following DTaP vaccination. Clin Exp Immunol 2012, 169:281-291.
• [57]Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, Grimprel E, Greenberg D, Halperin S, Liese J, Muñoz-Rivas F, Teyssou R, Guiso N, Van Rie A: Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007, 26:293-299.
• [58]Wendelboe AM, Hudgens MG, Poole C, Van Rie A: Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants. Emerg Themes Epidemiol 2007, 4:1-7. BioMed Central Full Text
• [59]Healy CM, Baker CJ: Infant Pertussis: What to Do Next? Clin Infect Dis 2012, 54:328-330.
• [60]Castagnini LA, Healy CM, Rench MA, Wootton SH, Munoz FM, Baker CJ: Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis 2012, 54:78-84.
• [61]Halperin BA, Morris A, Mackinnon-Cameron D, Mutch J, Langley JM, McNeil SA, Macdougall D, Halperin SA: Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis 2011, 53:885-892.
• [62]California Department of Public Health: California Department of Public Health. Pertussis Report, April 24, 2012. Available at: http://www.cdph.ca.gov/programs/immunize/Documents/PertussisReport2012-04-24.pdf webcite (accessed Dec 5, 2012)
• [63]Ulloa-Gutierrez R, Gentile A, Avila-Aguero ML: Pertussis cocoon strategy: would it be useful for Latin America and other developing countries? Expert Rev Vaccines 2012, 11:1393-1396.
• [64]Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R: Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012, 367:1012-1019.
• [65]Wei SC, Tatti K, Cushing K, Rosen J, Brown K, Cassiday P, Clark T, Olans R, Pawloski L, Martin M, Tondella ML, Martin SW: Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010, 51:315-321.
• [66]Quinn HE, McIntyre PB: The impact of adolescent pertussis immunization, 2004–2009: lessons from Australia. Bull World Health Organ 2011, 89:666-674.
• [67]Centers for Disease Control and Prevention (CDC): National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2011. MMWR Morb Mortal Wkly Rep 2012, 61:671-677.
• [68]Skoff TH, Cohn AC, Clark TA, Messonnier NE, Martin SW: Early Impact of the US Tdap vaccination program on pertussis trends. Arch Pediatr Adolesc Med 2012, 166:344-349.
• [69]Guiso N, Wirsing von König CH, Forsyth K, Tan T, Plotkin SA: The global pertussis initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11–12 January 2010. Vaccine 2011, 29:1115-1121.
• [70]WHO: Meeting of the Strategic Advisory Group of Experts on immunization, October 2009 Conclusions and recommendations. Biologicals 2010, 38:170-177.
• [71]Kretsinger K, Broder KR, Cortese MM, Joyce MP, Ortega-Sanchez I, Lee GM, Tiwari T, Cohn AC, Slade BA, Iskander JK, Mijalski CM, Brown KH, Murphy TV: Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006, 55:1-37.
• [72]Centers for Disease Control and Prevention (CDC): Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61:468-470.
• [73]Forsyth KD, von Konig CH W, Tan T, Caro J, Plotkin S: Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007, 25:2634-2642.
• [74]Purdy KW, Hay JW, Botteman MF, Ward JI: Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 2004, 39:20-28.
• [75]Poland GA: Pertussis outbreaks and pertussis vaccines: New insights, new concerns, new recommendations? Vaccine 2012, 30:6957-6959.
• [76]Beytout J, Launay O, Guiso N, Fiquet A, Baudin M, Richard P, Baptiste C, Soubeyrand B: Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Human Vaccine 2009, 5:315-321.
• [77]Scott LJ, McCormack PL: Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine, adsorbed (boostrix(®)): a guide to its use as a single-dose booster immunization against pertussis. BioDrugs 2013, 27:75-81.
• [78]Libster R, Edwards KM: Re-emergence of pertussis: what are the solutions? Expert Rev Vaccines 2012, 11:00.
• [79]Daskalaki I, Hennessey P, Hubler R, Long SS: Resource consumption in the infection control management of pertussis exposure among healthcare workers in paediatrics. Infect Control Hosp Epidemiol 2007, 28:412-417.
• [80]Bonmarin I, Poujol I, Levy-Bruhl D: Nosocomial infections and community clusters of pertussis in France, 2000–2005. Euro Surveill 2007, 12:11-12.
• [81]Hees L, Afroukh N, Floret D: Vaccination coverage among health care workers in the pediatric emergency and intensive care department of Edouard Herriot hospital in 2007, against influenza, pertussis, varicella, and measles. Arch Pediatr 2008, 16:14-22.
• [82]Millier A, Aballea S, Annemans L, Toumi M, Quilici S: A critical literature review of health economic evaluations in pertussis booster vaccination. Expert Rev Pharmacoeconomics Outcomes Res 2012, 12:71-94.
• [83]Rozenbaum MH, De Cao E, Westra TA, Postma MJ: Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around. Expert Rev Vaccines 2012, 11:1415-1428.
• [84]Fabricius G, Bergero PE, Ormazabal ME, Maltz AL, Hozbor DF: Modelling pertussis transmission to evaluate the effectiveness of an adolescent booster in Argentina. Epidemiol Infect 2013, 141:718-734.
• [85]Rozenbaum MH, De Cao E, Postma MJ: Cost-effectiveness of pertussis booster vaccination in the Netherlands. Vaccine 2012, 30:7327-7331.
• [86]Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, Lieu TA: Cost-effectiveness of pertussis vaccination in adults. Am J Prev Med 2007, 32:186-193.
• [87]Westra TA, de Vries R, Tamminga JJ, Sauboin CJ, Postma MJ: Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Ther 2010, 32:1479-1495.
• [88]Coudeville L, Van Rie A, Getsios D, Caro JJ, Crépey P, Nguyen VH: Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS One 2009, 4:e6284.
• [89]Skowronski DM, Janjua NZ, Tsafack ES, Ouakki M, Hoang L, De Serres G: The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization. Clin Infect Dis 2012, 54:318-327.
• [90]Scuffham PA, McIntyre PB: Pertussis vaccination strategies for neonates - an exploratory cost-effectiveness analysis. Vaccine 2004, 22:2953-2964.
• [91]Terranella A, Asay G, Messonnier M, Clark T, Liang J: Preventing infant pertussis: a decision analysis comparing prenatal vaccination to cocooning. Boston, MA: Presented at the 49th Infectious Diseases Society of America Annual Meeting; 2011.
• [92]Garlapati S, Eng NF, Kiros TG, Kindrachuk J, Mutwiri GK, Hancock RE, Halperin SA, Potter AA, Babiuk LA, Gerdts V: Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine 2011, 29:6540-6548.
• [93]Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, Younes AB, Creusy C, Engle J, Goldman WE, Locht C: Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PloS Pathog 2006, 2:e65.
• [94]Cornford-Nairns R, Daggard G, Mukkur T: Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate. J Microbiol Biotechnol 2012, 22:856-865.